Trials / Completed
CompletedNCT03472027
Phase I Study of BCD-145 (Anti-CTLA-4) in Patients With Unresectable/Metastatic Melanoma
A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of BCD-145 (JSC BIOCAD, Russia) in Patients With Unresectable/Metastatic Melanoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Biocad · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of BCD-145 (JSC BIOCAD, Russia) Monotherapy in Patients with Unresectable/Metastatic Melanoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | BCD-145 | Anti-CTLA-4 monoclonal antibody, IV infusion |
Timeline
- Start date
- 2017-10-02
- Primary completion
- 2018-09-11
- Completion
- 2018-12-04
- First posted
- 2018-03-21
- Last updated
- 2019-05-09
Locations
4 sites across 1 country: Russia
Source: ClinicalTrials.gov record NCT03472027. Inclusion in this directory is not an endorsement.